Novan to Report Full Year 2021 Financial Results on February 22, 2022
Novan (Nasdaq: NOVN) will release its full year 2021 financial results on February 22, 2022.
Rhea-AI Summary
Novan (Nasdaq: NOVN) will release its full year 2021 financial results on February 22, 2022. The management team, led by CEO Paula Brown Stafford, will hold a conference call at 8:30 a.m. ET to discuss both operational and financial outcomes. Investors can participate by calling (844) 707-0661 domestically or (703) 318-2240 internationally, using conference ID: 4368839. The live audio webcast will be available on the Novan website and archived for 90 days. Novan focuses on nitric oxide-based therapies in dermatology and anti-infectives.
Positive
- None.
Negative
- None.
Details
News Market Reaction – NOVN
The recorded move for NOVN in the trading session of this news was +5.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2021 financial results on Tuesday, February 22nd. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.
The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (844) 707-0661 (domestic) or (703) 318-2240 (international) and referencing conference ID: 4368839. The live webcast will be accessible on the Events page of the Investors section of the Novan website, novan.com, and will be archived for 90 days.
About Novan
Novan, Inc. is a pre-commercial nitric oxide-based pharmaceutical company focused on dermatology and anti-infective therapies. We leverage our core synergies of science, capital, resources and patient needs to create value by bringing new nitric oxide-based medicines to market. Our goal is to create the world’s leader in nitric oxide-based science, technology, and clinical translation in support of delivering safe and efficacious therapies using our proprietary nitric oxide-based technology platform, NITRICIL™ to generate macromolecular New Chemical Entities (NCEs) to treat multiple indications.
INVESTOR AND MEDIA CONTACT:
Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.